TOVX Stock — Theriva Biologics Inc.: Cash, EV, Pipeline

Share price

$0.23

Market cap

$10.7M

Cash

$11.3M

Enterprise value

$1.1M

Balance sheet

Cash	$11.3M
Debt	$1.7M
Net cash	$9.6M
Enterprise value	$1.1M
Basic shares	45.9M shares
Fully diluted shares	63.3M shares
Fully diluted market cap	$14.6M
Cash per share	$0.25

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading TOVX daily closes…

Loading price history…

Pipeline assets

VCN-01

Phase 2 · Active Modality: oncolytic adenovirus (genetically modified, intratumoral or IV)

Aliases zabilugene almadenorepvec

Target hyaluronan

Partnerships Catalan Institute of Oncology: investigator-sponsored Phase 1 study; University of Pennsylvania: clinical trial agreement for Phase 1 huCART-meso cell combination study

Indications

pancreatic ductal adenocarcinoma (VIRAGE Phase 2b, IV with gemcitabine/nab-paclitaxel) (Phase 2)
refractory retinoblastoma (investigator-sponsored Phase 1) (Phase 1)

Status note Lead product candidate; genetically modified oncolytic adenovirus based on HAd5. FDA Orphan Drug designation (June 2023) and Fast Track (May 2024) for pancreatic cancer; EMA COMP orphan recommendation (May 2011) for pancreatic cancer. VIRAGE Phase 2b randomized study ongoing; Phase 1 retinoblastoma data presented May 2025. Additional preclinical/clinical combination work (liposomal irinotecan, immunomodulators) not distinct assets.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	SYN-004
Lead indication	Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04692181	Phase 2	Active, not recruiting	Sponsor	TOVX	—	Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant; Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Theriva Biologics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	112,076	no change	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

TOVX — Theriva Biologics Inc.